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Abstract
Background: Cell lines constitute a powerful model to study cancer, and here we describe three
new epithelial ovarian cancer (EOC) cell lines derived from poorly differentiated serous solid
tumors (TOV-1946, and TOV-2223G), as well as the matched ascites for one case (OV-1946).
Methods: In addition to growth parameters, the cell lines were characterized for anchorage
independent growth, migration and invasion potential, ability to form spheroids and xenografts in
SCID mice.
Results: While all cell lines were capable of anchorage independent growth, only the TOV-1946
and OV-1946 cell lines were able to form spheroid and produce tumors. Profiling of keratins, p53
and Her2 protein expression was assessed by immunohistochemistry and western blot analyses.
Somatic TP53 mutations were found in all cell lines, with TOV-1946 and OV-1946 harboring the
same mutation, and none harbored the commonly observed somatic mutations in BRAF, KRAS or
germline BRCA1/2 mutations found to recur in the French Canadian population. Conventional
cytogenetics and spectral karyotype (SKY) analyses revealed complex karyotypes often observed
in ovarian disease.
Conclusion: This is the first report of the establishment of matched EOC cell lines derived from
both solid tumor and ascites of the same patient.
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Background
Epithelial ovarian cancer (EOC) is often described as the
silent killer or the disease that whispers mainly due to
absence of symptoms. This combined with the lack of spe-
cific/sensitive markers and/or techniques of screening
leads to the diagnosis at late stages of the disease in more
than 70% of patients. Unfortunately, the five year survival
rate at this point of the disease is less than 30% [1].
Although EOC is not the most prevalent of cancers, it
accounts for the highest number of deaths from a gyneco-
logic malignancy.
EOC is a complex disease stratified according to his-
topathological and morphological criteria. The majority
of EOCs are thought to arise from the ovarian surface epi-
thelium (OSE) that is derived from the coelomic epithe-
lium. OSE is composed of multipotent cells that can
differentiate and give rise to tumors of different histopa-
thology types [1,2]. The latter are defined by the Interna-
tional Federation of Gynecology and Obstetrics (FIGO)
[3] and represent serous, endometrioid, mucinous, clear
cell, de Brenner, mixed and undifferentiated subtypes.
Serous type tumors are the most common subtype of EOC
identified in more than 50% of cases. EOC tumors are
graded according to the degree of differentiation of tumor
cells which can vary from well (grade 1), moderately
(grade 2) or poorly (grade 3) differentiated cells. Finally,
EOC tumors are also classified according to the spread of
the disease varying from stage I when tumors are confined
to the ovaries to stage IV when distant metastases are
observed.
Over the past years several laboratories, including ours
[4], have established and characterized cell lines derived
from EOC tumors. However, the majority of these EOC
cell lines were established from patients ascites [4-29] and
only few were derived from solid tumors [4,12,30-37].
Moreover, EOC cell lines have rarely been derived from
chemotherapy-naive patients while others were estab-
lished following viral transformation (SV40 Large T anti-
gen) (such as NMSO cell line) [38,39] or xenograft
passage in immunocompromised mice (such as the HEY,
HO-8910PM, and AMOC-2 cell lines) [10,40,41]. In addi-
tion, few cell lines derived from serous EOC tumors are
available even though this subtype represents the most
frequently occurring histopathology subtype (such as the
TOV-81D, FU-OV-1, and HOC1-7 cell lines)
[4,10,11,33,35].
In this study, we describe three new serous EOC cell lines
that were derived in our laboratory from either solid
tumors or ascites of two chemotherapy-naïve patients.
This is the first report characterizing cell lines derived
from both solid tumor and ascites of the same patient.
Moreover, the molecular and growth characteristics of the
three cell lines present some unique features thereby pro-
viding the research community with new tools in the
study of different aspects of serous EOC.
Methods
Sample and Patient data
Tumor samples were collected and banked following sur-
geries performed within the Division of Gynecologic
Oncology at the Centre hospitalier de l'Université de
Montréal (Hôpital Notre-Dame). The study was approved
by the CHUM institutional ethics committee and written
consent was obtained from patients prior to sample col-
lection. Stage was determined at the time of surgery. His-
topathology and tumor grade were assigned by a
pathologist according to the International Federation of
Gynecology and Obstetrics (FIGO) criteria [3].
Establishment of the cell lines and culture conditions
All primary cultures and cell lines were cultured in OSE
medium (Wisent, Qc, Canada) supplemented with 10%
fetal bovine serum (FBS), 2.5 μg/ml amphotericin B and
50 μg/ml gentamicin. Cells were incubated in 5% CO2
and 5% O2.
The TOV-1946 cell line was established using the previ-
ously described scrape method on tumor tissue from
patient 1946 [42,43]. Briefly, tumor tissue was gently
scraped into a 100 mm petri dish containing supple-
mented OSE medium. TOV-1946 cells were maintained in
the same petri dish for the first 40 days and medium was
replaced weekly. After 40 days, 80% confluence was
attained and TOV-1946 cells were divided into two petri
dishes. They were then divided in a proportion of 2:3 once
a week for the first 15 passages and 1:2 twice a week there-
after until passage 70. Subsequently, cells were main-
tained and divided in a proportion of 1:5 twice a week.
The OV-1946 cell line was established from a mass of cells
from the ascites of patient 1946. The mass was macro-dis-
sected into small pieces, which were kept in a 100 mm
petri dish for 27 days at which point adherent cells
reached 80% confluence. Pieces of tissue were then dis-
carded. Cells were divided in a proportion of 2:3 every
week for the first 15 passages and then 1:2 twice a week
until passage 70. Cells were then maintained and divided
in a proportion of 1:5 twice a week.
The TOV-2223 cell line was established from patient 2223
tumor tissue using the collagenase method. Briefly, tumor
tissue was macro-dissected onto a 100 mm petri dish con-
taining serum free OSE medium supplemented with 1000
U of collagenase (Sigma-Aldrich, ON, Canada). After 3–4
hours at 37°C, cells were resuspended into 8 ml of
medium and the remaining tumor tissue pieces were dis-
carded. The medium containing cells was then dividedBMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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into four 60 mm petri dishes and 10% FBS was added.
Cells were divided 1:2 once a week until passage 19 and
then twice a week until passage 70. Subsequently, cells
were maintained and divided in a proportion of 1:3 twice
a week.
Antibodies
For immunohistochemistry and western blot analyses, the
following antibodies were used: beta actin AC-15 (ab6276
from Abcam inc. MA, USA), p53 (D0-1) (sc-126 from
Santa Cruz Biotechnology, CA, USA), anti-c-ErbB2/c-Neu
(OP15, Calbiochem, ON, Canada), Keratin 19 Ab-1
(Ms198-P0, Lab Vision Corp., CA, USA), Keratin 7 Ab-2
(MS-1352-P0) and Keratin 8 Ab-4 (MS-997-P0, both from
NeoMarker, Medicorp, Qc, Canada).
Immunohistochemistry
Formalin fixed paraffin embedded tumors were sectioned
at 4 μm and the slides were stained using the immunoper-
oxidase method. Briefly, tissue sections were heated at
60°C for 30 minutes, deparaffinized in toluene and rehy-
drated in an ethanol gradient. Slides were submerged in
boiling citrate buffer (0.01 M citric acid adjusted to pH
6.0) and microwaved for 10 min to unmask antigens. A
3% H2O2 treatment was used to eliminate endogenous
peroxidase activity. The sections were blocked with a pro-
tein blocking serum-free reagent (DakoCytomation Inc.,
ON, Canada) and incubated with different antibodies for
60 min at room temperature.
The optimal concentration for each primary antibody was
determined by serial dilutions. Tissues were incubated
with either a secondary biotinylated antibody (DakoCyto-
mation Inc., ON, Canada) or a rabbit anti-goat biotin-
conjugated antibody (1:300) (sc-2774, Santa Cruz Bio-
technology, CA, USA) for 20 min followed by incubation
with a streptavidin-peroxidase complex (DakoCytoma-
tion Inc., On, Canada) for 20 min at room temperature.
Reaction products were developed using diaminobenzi-
dine containing 0.3% H2O2 as a peroxidase substrate.
Nuclei were counterstained with hematoxylin and all sec-
tions were observed by light microscopy at 400× magnifi-
cation. Substitution of the primary antibody with
phosphate buffered saline served as a negative control.
Growth rate
Growth rates were assessed as previously described [4].
On day 0, 1 × 105 cells were seeded onto 60 mm petri
dishes. On day 1, 3, 5, 7, 9, 11 and 13 the cells were
trypsinized, resuspended in medium and counted using a
hemacytometer. Each experiment was performed in tripli-
cate for each harvest and repeated once. Saturation den-
sity was defined as the mean maximum number of cells at
confluence counted from two independent experiments
performed with triplicates and the doubling time was cal-
culated according to the slope of the linear portion of the
growth curve.
Anchorage independent growth in soft agarose and three-
dimensional culture
Cell lines were assayed for their ability to grow in anchor-
age independent conditions by culturing 1 × 104 cells in
agarose (0.33 g/100 ml OSE complete medium for the
upper layer and 0.66 g/100 ml OSE complete medium for
the base layer) [43]. Cells were cultured in soft agar for
three weeks, colonies were photographed and these were
used for counting. Two independent experiments per-
formed in duplicate.
Cell lines were tested for their ability to form three-dimen-
sional aggregates or spheroids as previously described
[44,45]. Briefly, 4000 cells were suspended in 15 μl of
OSE complete medium. The droplets of medium contain-
ing cells are then placed on the cover of non-coated plastic
tissue culture plate. The cover is placed on a dish contain-
ing 10 ml of PBS to prevent dehydration of the droplets.
The ability to form spheroids was assessed after four days.
Low serum growth
Tumor cell growth in low serum conditions was assessed
by plating cells in six well plates in OSE medium supple-
mented of 1% FBS, 2.5 μg/ml amphotericin B and 50 μg/
ml gentamicin and cultured for 21 days. The medium was
changed every seven days. The experiments were per-
formed in duplicate.
Wound-healing assay
Migration potential was evaluated using the scratch assay
method as previously described [46-48]. Briefly, cells were
plated onto a 12 well dish and once the cell confluence
reached about 90% wounds were created using a 200 μl
plastic tip. In order to evaluate cell migration into the
wound, cells were methanol fixed and treated with
Giemsa Stain (Sigma-Aldrich Inc., MO, USA) at 0, 8, 24
and 48 hours after creating the wound. The experiments
were performed twice in triplicate.
In vitro invasion assay
Cellular invasion was assayed by the ability of cells to
invade a synthetic basement membrane (Matrigel, Bec-
ton-Dickenson, NJ, USA) using Boyden chambers. Poly-
carbonate membranes (8 μm pore size) of the upper
compartment of transwell culture chambers were coated
with 0.4 μg/ml Matrigel. Ovarian cancer cells were
trypsinized and resuspended in OSE medium supple-
mented with 1% FBS. The cell suspension (20 × 103 cells/
well) was placed in the upper compartment of the Boyden
chamber, and the lower compartment was filled with OSE
medium with 5% FBS. Cells were incubated at 37°C for
24 hours. Following incubation, membranes were metha-BMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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nol fixed and stained with Giemsa Stain (Sigma-Aldrich
Inc., MO, USA). Non-invading cells were removed with a
cotton swab, while invading cells on the underside of the
membrane were counted using an inverted microscope.
The experiments were performed in duplicate.
In vivo growth in SCID mice
The tumorigenic potential of cell lines was assessed based
on their ability to form tumors in 45 day-old female SCID
mice at subcutaneous (s.c.) left gluteal or intraperitoneal
(i.p.) injection sites. Each mouse was injected with 5 × 106
cells suspended in phosphate buffered saline (PBS). The
animals were housed under sterile conditions in a laminar
flow environment with ad-lib access to food and water.
Tumor formation was assessed over 180 days. Animals
were sacrificed before neoplastic masses reached limit
points established by the Institutional Committee on Ani-
mal Protection (CIPA) according to the Canadian Council
on Animal Care.
Mutation analyses
TP53 mutations were detected by single-strand conforma-
tion polymorphism (SSCP) analysis of cell line DNA.
Polymerase chain reaction (PCR) was used to amplify
exons 5–9 of TP53 as previously described [49]. Muta-
tions were detected as band shift relative to the wild-type
pattern, and confirmed by sequence analysis (McGill Uni-
versity and Genome Quebec Innovation Centre, Mon-
treal, Quebec, Canada). If negative by the SSCP assay,
samples were sequenced for exons 2–11 (translated
region), as previously described [50]. KRAS was investi-
gated by sequencing genomic regions corresponding to
codons 12 and 13 as previously described [51]. Microsat-
ellite instability (MSI) was established as previously
described [4].
BRAF exons 11 and 15 were analyzed by SSCP analysis.
PCR was performed in a 12.5 μl volume containing 200
ng of genomic DNA; 1.25 μCi of [35S]dATP (Perkin-
Elmer, ON, Canada); 1× PCR buffer (Invitrogen, ON,
Canada); 2.5 nmol each dCTP, dGTP and dTTP; 0.3 nmol
dATP; 1.5 mM MgCl2; 15 pmol of each primer [52]; and
0.5 U of Taq DNA polymerase (Invitrogen, ON, Canada).
The PCR conditions were 3 min at 95°C, 35 cycles of
94°C for 30 sec, 55°C for 30 sec and 72°C for 30 sec. The
reaction products were diluted 2:3 with stop buffer (90%
formamide, 10 mM EDTA, 10% bromophenol blue and
10% xylene cyanol) and heated at 95°C for 10 min before
loading on a 0.5× MDE (Mandel Scientific, ON, Canada)
non-denaturing gel. The products were electrophoresed at
25 W at 4°C for 6 h. Gels were dried at 80°C and autora-
diographed at room temperature for 2–3 days on Kodak
Biomax MR film (Perkin-Elmer, ON, Canada). Mutations
were detected as band shift relative to the wild-type pat-
tern, and confirmed by sequence analysis (McGill Univer-
sity and Genome Quebec Innovation Centre).
The common French Canadian founder mutations
4446C>T and 2953delGTAinsC in BRCA1  and
8765delAG, 6085G>T and 3398delAAAAG in BRCA2
were investigated in DNA from patient matched periph-
eral blood lymphocytes as described [53,54].
Conventional cytogenetics and Spectral Karyotyping (SKY) 
of the cell lines
Metaphase preparation and cytogenetic analyses with a
trypsin-Giemsa banding technique of the TOV-2223,
TOV-1946 and OV-1946 ovarian cancer cell lines were
performed according to standard cytogenetic procedures.
Clonal chromosomal abnormalities and GTG-banded
karyotypes were described according to the International
System for Human Cytogenetic Nomenclature [55]. Met-
aphase cells from the same culture passage were used for
standard and spectral karyotyping of each ovarian cancer
cell line. Slide pretreatment, hybridization with the Sky-
Paint™ human probes and detection were performed with
the protocol provided by Applied Spectral Imaging (ASI)
[56] with minor modifications. Spectral images were
acquired with a SpectraCube® system (ASI) mounted on a
Zeiss Axioplan II microscope and analyzed using the Sky-
View version 1.6.1 software (ASI).
Results
Primary culture, cell line and tumor tissue phenotype
Cell lines were derived from both solid tumors (TOV-
1946 and TOV-2223G) and ascites (OV-1946) of two
chemotherapy naive patients. Patients 1946 and 2223
from which the cell lines were derived both presented
poorly differentiated (grade 3) serous papillary cystaden-
ocarcinoma at stage IIIC. Based on residual tumor present
following surgery, both patients were considered to be
suboptimaly debulked. Patient 2223 received a palliative
treatment only and survived for 18 months while patient
1946 died from post-operative complications. Patient
1946 did not have any known familial history of cancer.
However, two sisters of patient 2223 were diagnosed with
ovarian cancer (70 and 80 years old) and numerous colon
cancers were diagnosed within the family. Clinical data
for both patients are summarized in Table 1.
At initial passage all three cell lines appeared more (TOV-
1946 and TOV-2223) or less (OV-1946) heterogenous
with populations of cells with obvious fibroblastic con-
taminants (Figure 1A,C,E). With subsequent passages a
selection toward a more homogenous population of cells
occurred and cell lines presented a cobblestone morphol-
ogy characteristic of epithelial cells (Figure 1B,D,F).BMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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Hematoxylin-Eosin stained tumor tissue sections of
patient 1946 and 2223 (Figure 1G and 1H, respectively)
presented typical poorly differentiated tumor masses.
While all cell lines exhibited similar cobblestone mor-
phologies typical of epithelial cells, the TOV-2223 cells
are larger than the TOV-1946 and OV-1946 cells (Figure
1B,D,F). This reflects morphological differences in the
corresponding tumor tissues where cells in the TOV-2223
tumors were larger than those observed in the 1946 tumor
(Figure 1G,H).
One of the hallmarks of cancer cells is their ability to grow
in the absence of exogenous growth factors, which can be
verified by culturing cancer cells in low serum conditions.
All cell lines were able to grow in a medium containing
only 1% of FBS. In general however, growth rates were
slower in low serum conditions than those observed in a
typical 10% FBS environments (data not shown).
Solid tumor and cell line expression of keratins, TP53 and 
HER2
In order to further establish the epithelial characteristics
of our cell lines keratin expression was assessed. Both
TOV-1946 and OV-1946 cell lines expressed Krt7 and
hence mirror keratin expression observed in vivo in the
original tumor (Figure 2A and 2I). However, the TOV-
1946 cell line expressed a much higher level of this keratin
when compared to its ascites counterpart (Figure 2I). As
reflected by immunohistochemistry and western-blot
analyses, although TOV-2223 tumor tissue expressed
Krt7, the corresponding cell line seems to have lost the
capacity to express this particular keratin (Figure 2E and
2I). The epithelial characteristics of the cell lines were also
verified by the expression of Krt18 and Krt8, which are
also markers of epithelial cells. The expression of these
keratins was observed only in the TOV-2223 cell line (Fig-
ure 2I). The gastro-intestinal tract tumor marker Krt20 was
absent in both tumor tissues and all cell lines (Figure 2B
and 2F).
We assessed the expression of p53 and Her2 in both orig-
inal tumor tissues and cell lines. Tumor tissues from both
patients exhibited Her2 expression (Figure 2C and 2G),
however the level of expression was stronger in the TOV-
2223 tumor tissue (Figure 2G). This is concordant with
Her2 expression in the cell lines by western blot analysis
(Figure 2I). We also examined p53 expression by immu-
nohistochemistry. Positive staining with the p53 antigen
is often indicative of TP53 gene mutation. The tissue from
patient 1946 exhibited positive nuclear staining for p53
(Figure 2D) in contrast to that observed with the tumor
from the patient 2223 (Figure 2H). p53 positive immuno-
reactivity was mirrored in the cell lines by western blot
(Figure 2I).
Cell growth rate and tumorigenicity assays
The growth characteristics of the new cell lines were also
assessed (Table 2 and Figure 3) and compared to TOV-
112D, a cell line previously established and characterized
in our laboratory [4]. The new EOC cell lines exhibited
slower growth rates than the very aggressive TOV-112D
reference cell line (Table 2 and Figure 3A). TOV-1946 has
the shortest doubling time (1.3 days) when compared to
the other two new cell lines (2.5 and 2.6 days for OV-1946
and TOV-2223 respectively). All cell lines exhibited simi-
lar saturation density although inferior (almost half) to
that of TOV-112D. These results are consistent with the
observation that TOV-112D exhibited small cells with a
tendency to compact and form foci [4] as opposed to
TOV-1946 and TOV-2223 cell lines which respectively
show cells of medium and large size. The capacity of the
new cell lines to form foci at high cell inocula and density
Table 1: Patient clinical data
Patient
Clinical Parameter 1946 2223
Age at diagnosis 75 89
Tumor type cystadenocarcinoma cystadenocarcinoma
Histopathology sub-type serous papillary serous papillary
Tumor grade G3 G3
Disease stage IIIC IIIC
Ascitis at surgery Yes yes
Surgical debulking Sub-optimal Sub-optimal
Progression N/A yes
Death yes* yes
Cause of death gastric hemorrhage disease progression
Follow up (months) 0.5 18
Treatment N/A Megace (palliative care only)
N/A = not applicable
*patient died from post-operative complicationBMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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Cellular morphology of serous ovarian epithelium cancer cell lines and their corresponding tumoral tissues Figure 1
Cellular morphology of serous ovarian epithelium cancer cell lines and their corresponding tumoral tissues. A, 
C, E) Morphological appearance of the TOV-1946, OV-1946 and TOV-2223 cell lines respectively at passage 0. More (TOV-
1946 and TOV-2223) or less (OV-1946) heterogenous populations of cells with obvious fibroblastic contaminants are visible 
for all three cell lines. B,D,F) Appearance of TOV-1946, OV-1946 and TOV-2223 cell lines respectively at passage 70. An evo-
lution toward a more homogenous population of cobblestone-like cells typical of an epithelial cell type. G,H) Hematoxylin-
Eosin stained tumor tissue sections of patient 1946 and 2223. Poorly differentiated tumor masses can be observed. All primary 
cultures and cell lines were cultured in OSE medium composed of 50:50 medium 199:105 (Sigma) supplemented with 10% fetal 
bovine serum (FBS), 2.5 μg/mL amphotericin B and 50 μg/mL gentamicin. All photographs were taken at 400× magnification.BMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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Solid tumor and cell line expression of keratins, TP53 and HER2 Figure 2
Solid tumor and cell line expression of keratins, TP53 and HER2. A-D) Immunohistochemistry on paraffin embedded 
TOV-1946 tumor tissue verifying Krt7, Krt20, Her2 and p53 expression respectively. E-H) Expression of the same four pro-
teins was verified in the TOV-2223 tumoral tissue. Krt7 and Krt20 were used to distinguish between ovarian and gastro-intes-
tinal tract tumors. Nuclei were counterstained with hematoxylin and all sections were observed by light microscopy at 400× 
magnification. I) In parallel, Her2, p53, Krt7, Krt18 and Krt8 expression was verified by western blot in cell lines. Krt7, Krt18 
were used in order to confirm the epithelial character of cell lines. Actin was used as a loading control.BMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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was also verified and confirmed. The cell lines described
here exhibit all the qualities of an established immortal-
ized cell lines as they were all kept in culture for more than
150 passages.
To further characterize the new cell lines, the migration
potential was assessed (Table 2 and Figure 3B). TOV-1946
cells migrated faster than the other three cell lines, as they
were able to close the wound in 24 hours. The migration
patterns of TOV-112D and OV-1946 were similar and
filled the wound in 48 hours. However, TOV-2223
migrated more slowly and needed more than 48 hours to
close the wound.
Using the modified Boyden chambers, we then measured
the capability of the cells to invade through matrigel
membranes (Table 2 and Figure 3C). We noted an
increase in invasion potential from TOV-112D, OV-1946,
TOV-2223 and TOV-1946, where TOV-112D was the least
invasive and TOV-1946 the most invasive.
We next monitored the capacity of the cells to form three-
dimensional structures in hanging droplets, a method
routinely used in our laboratory. Only TOV-112D cells
were able to form very compact spheroids, OV-1946
formed less compact spheroids, TOV-1946 cells formed
loose aggregates of cells. The TOV-2223 cells were unable
to form any aggregates and cells were individually spread
across the droplet (Table 2 and Figure 3D).
We next measured the capability of the cell lines to grow
in an anchorage independent environment by culturing
the cells in soft agarose (Table 2). All cell lines were able
to form colonies in soft agarose. The size of the colonies
were similar for TOV-112D, TOV-1946 and OV-1946 but
were larger than TOV-2223. The number of colonies
increased from TOV-1946, TOV-2223, OV-1946 and TOV-
112D with TOV-1946 having the lowest number of colo-
nies and TOV112D the highest.
Finally, we monitored the potential of in vivo growth by
injecting tumor cells at intraperitoneal or subcutaneous
sites in SCID mice (Table 2). Subcutaneous tumors were
observed only for the TOV-112D cell line. However, intra-
peritoneal (IP) tumors were also observed for the
TOV1946 and OV1946 cell lines. The TOV-1946 cell line
formed tumors in only 3 mice and only after an average of
125 days. The OV-1946 cell line formed tumors more rap-
idly (average 63 days) and a greater number of tumors (5
mice). The TOV2223 cell lines did not form tumors in
Table 2: Summary of cell line growth characteristics and tumorigenicity
Cell line growth assays TOV-1946 OV-1946 TOV-2223 TOV-112D
Growth 
characteristic
Doubling time (days) +/- S.D.a 1.3 +/- 0.4 2.5 +/- 0.9 2.6 +/- 0.7 1.0 +/- 0.2
Saturation density (nb cells +/
- S.D.)b
3 053 933 +/- 153 
933
3 231 400 +/- 962 
723
2 536 867 +/-680 
852
6 162133 +/- 515 034
Number of passages to date >210 >210 >150 >200
Spheroid Formation aggregate semi-compact no compact
Migration time for wound filling (h) 24 48 >48 48
Invasion Mean number of cells +/- 
S.D.c
417 +/- 226 149 +/- 70 257 +/- 79 118 +/- 34
Soft agarose Colony number +/- S.D.d 11 +/- 3 24 +/- 8 16 +/- 4 27 +/- 10
Colony size large large small large
Low serum Capacity to grow in low 
serum (1%) conditions
yes yes yes yes
Subcutaneous 
injection in SCID 
mice
Number of mice with tumors 
(n = 6)
0005
Mean time of tumor 
appearance (days)
N/A N/A N/A 7
Intraperitoneal 
injection in SCID 
mice
Number of mice with tumors 
(n = 6)
3506
Mean time of tumor 
appearance (days)
125 63 N/A 18
Number of mice with ascitis 2 1 0 2
N/A not applicable
acalculated according to the slope of the linear portion of the growth curve.
brepresents the mean of maximum number of cells counted among the two independent experiments performed in triplicatat
cnumber of cells that migrate through the matrigel insert
dmean of colony numbers per representative area (minimum 5) from two independent experiment performed in duplicateBMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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Cell growth rate and tumorigenicity assays Figure 3
Cell growth rate and tumorigenicity assays. A) Growth curves of the three new cell lines as well as a previously charac-
terized EOC TOV-112D cell line. 100 000 cells were plated onto 60 mm petri dishes. Cells were trypsinised and counted 
every 48 h for two weeks. Experiments were performed two times in triplicate. B) Wound-healing assay of the same four cell 
lines. Cells were plated onto a 12 well dish and at near confluence wounds were generated. Cells were methanol fixed and 
treated with Giemsa Stain at different time points in order to evaluate cell migration (0 h, 8 h, 24 h and 48 h after the scratch 
was performed). The experiments were performed twice in triplicate. C) Invasion assay using modified Boyden chambers. The 
capability of the cells to invade through matrigel membranes was verified and the invasion potential increased from TOV-112D, 
OV-1946, TOV-2223 to TOV-1946. The experiments were performed in duplicate. D) The capacity of the cells to form three-
dimensional structures in hanging droplets was monitored. TOV-112D cells were able to form very compact spheroids, OV-
1946 formed less compact spheroids, TOV-1946 cells formed loose aggregates of cells and TOV-2223 cells were unable to 
form any 3-D structure. Spheroid formation capability was visualized after four days.BMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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mice (Table 2) however one mouse showed very small
masses on liver lobes when all mice were sacrificed at
approximately seven months post-injection (data not
shown).
Mutation status of the new EOC cell lines
In order to further characterize the cell lines, we per-
formed somatic mutation analysis of TP53, KRAS, and
BRAF  as well as assayed for evidence of microsatellite
instability (Table 3). Germline mutation (BRCA1  and
BRCA2) analysis was limited to the recurrent mutations
found in women of French-Canadian descent as cell lines
were derived from patients of this ancestral origin [53].
Sequence variations in TP53 were identified in the DNA
from all three EOC cell lines (Table 3). The same variant
in exon 8, which is expected to confer an amino acid sub-
stitution of arginine to cysteine at codon 273, was identi-
fied in both TOV-1946 and OV-1946. The TP53 sequence
variants are classified as deleterious mutations in the IARC
TP53 mutation database [57,58]. The TP53 mutation sta-
tus of TOV-1946 and OV-1946 is consistent with IHC
results in these cell lines (Figure 2D and 2I). Although
TOV-2223 harbors a TP53 mutation, IHC staining was
negative (Figure 2). This is not inconsistent with inde-
pendent reports that only a smaller fraction of cancers
(about 12%) harboring nonsense mutations exhibited
IHC-positivity as compared to IHC-negative nonsense
mutations (IARC TP53 mutation database) [57]. As TP53
mutation analysis revealed no evidence of heterozygosity,
it is likely that no functional p53 is encoded in these cell
lines. No mutations in the other genes studied were found
in the cell lines.
Cytogenetics and Spectral Karyotyping
The cytogenetic alterations of the three cell lines were
assessed by G-banded karyotyping and by spectral karyo-
typing (SKY). Twenty-five metaphases in G-banding and
thirty-two metaphases in SKY (TOV-2223), twenty-two
metaphases in G-banding and thirty-nine metaphases in
SKY (TOV-1946) and nineteen metaphases in G-banding
and fifteen metaphases in SKY (OV-1946) were analyzed.
The G-banded analysis of the three cell lines revealed a
modal number of 51 to 71 chromosomes with complex
karyotypes that are described as a composite karyotype
containing the clonal chromosomal abnormalities (Table
4) [55].
For the definition of the chromosomal breakpoints and
the characterization of the marker chromosomes, the
inverted-DAPI banding and spectral images were com-
pared with the SKY-painted chromosomes of the same cell
and then studied with the G-banded karyotypes for each
cell line. This method allows a better identification of the
numerous chromosomal rearrangements and several
markers in each cell line. It is noteworthy that there were
common but also unique chromosomal abnormalities
when comparing the TOV-1946 and OV-1946 cell lines.
Some representative metaphases are shown in Figures 4, 5
and 6 (see also Additional Files 1, 2, 3, 4, 5).
Discussion
In order to establish new cellular models of EOC, all sam-
ples of ovarian tissues collected for our tumor banks are
processed to derive primary cell cultures. Occasionally,
some of the primary cultures evolve to become immortal
cell lines. So far, we have been successful in establishing
seven EOC cell lines [4], three of which are described here.
All cell lines were derived from patients who were never
exposed to chemotherapy. This is of importance, since the
majority of available cellular models originate from sam-
ples obtained following neoadjuvant therapy that could
introduce genetic events not related to the biology of the
disease.
Early in culture, cell lines presented heterogenous popula-
tions of cells that eventually progressed toward a more
uniform population of cells with cobblestone-like mor-
phology typical of epithelial cells. All cell lines grew as
Table 3: Mutations status of the new EOC cell lines
Gene tested TOV112D TOV-1946 OV-1946 TOV-2223G
Somatic
TP53 EX5-36 G>A, R175H EX8+35 C>T, R273C EX8+35 C>T, R273C EX4+62 G>A, W53X
KRAS ----
BRAF ----
Microsatellite Instablility (MSI) - - - -
Germline
BRCA1 ----
BRCA2 ----
- = no mutations were foundBMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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adherent monolayers without evidence of cellular piling.
However, we noted that TOV-2223 cells were more adher-
ent to the petri dish when compared to TOV- and OV-
1946. Indeed, a longer trypsinization time is required to
detach these cells from the petri dish. Also, when fixed in
methanol, a large portion of both 1946 cell lines detached
from the solid support while 2223 cells did not (data not
shown). The homogeneity of cells observed at passage 0 of
OV-1946 could reflect the fact that these cells came from
a mass in the patient's ascites that is more homogenous
then a tumor mass often composed of, among others, epi-
thelial tumor cells, stromal cells and endothelial cells.
Cell lines were also evaluated on their capacity to survive
and grow in low serum conditions. It is worth noticing
that although in normal growth conditions both TOV and
OV-1946 cell lines present similar growth rates, in low
serum conditions the later is almost two times slower.
This could be in line with the fact that the OV-1946 cell
line comes from ascites which is rich in growth factors and
in culture can replace FBS [59]. This cell line could hence
be more dependent on growth signals provided by the
environment as opposed to cells originating from solid
tumors where cells may be predicted to be more self-suffi-
cient.
In epithelial cells, intermediate filaments are composed of
keratins that vary according to the differentiation of the
cells. Both OSE and EOC tumors are characterized by the
expression of different keratins such as KRT7, KRT8 and
KRT18. In order to determine if our cell lines presented
these EOC markers, we monitored protein expression of
Krt7, Krt8 and Krt18 by western blot. When antibodies
were appropriate for immunohistochemistry on paraffin
embedded tissues, we also compared keratins expression
in the original tumor tissues. It is also well described that
monitoring expression of Krt7 and Krt20 could distin-
guish between ovarian and gastro-intestinal tract tumors
(reviewed in [60]). Both the 1946 and the 2223 patients
presented different epithelium specific Krt expression
(Figure 2A and 2E) but did not express Krt20. It is worth
noting that the Krt patterns were not all the same between
different cell lines. Stronger expression of Krt7 is observed
in TOV-1946 and TOV-2223G was the only cell line that
expressed Krt18 and Krt8. This underlines the fact that
these cell lines are biologically different even though they
originate from tissues representing the same type of serous
EOC disease. Moreover, Krt7 is also differentially
expressed between the TOV-1946 and OV-1946 cell lines
that not only originate from the same type of disease but
also from the same patient and differences are related to
solid tumor versus ascites.
In EOC, 25 to 30% of the tumors present an amplification
of the HER2 gene leading to the overexpression of the pro-
tein Her2 (reviewed in [2,61-63]). The overexpression of
this growth factor receptor alone was shown to be suffi-
cient to induce malignant transformation and is impli-
cated in ovarian cancer as well as many other types of
cancer [64-67]. In EOCs of advanced stage, over 50% of
the tumors were shown to be mutated in the TP53 gene
(reviewed in [2,61-63]). All three cell lines showed Her2
protein expression and contained TP53 gene mutations.
Differences in growth rates, migration, invasion and sphe-
roid formation between the TOV-1946 and TOV-2223
underline the diversity of phenotypes that can be
observed within the same type of serous EOC disease. The
results from the comparison of the TOV-1946 and OV-
1946 growth characteristics, demonstrate that these cell
Table 4: G-banding composite karyotypes of the three ovarian cancer cell lines
Cell line G-banding composite karyotypes
TOV-2223 53~71, X, der(X)t(X;2)(q13;q2?3), +der(1)t(1;17)(p3?4;q21), +add(1)(p?21), +add(1)(p12),?i(2)(q10), der(2)t(2;5)(q31;q31), 
+der(3)t(3;22)(q2?2;q11.2), del(3)(q23), +4, +4, -5, +5, der(6;12)(q10;q10), +add(6)(p11.2), +7, del(8)(p11.2)x2, +del(8)(p21), +9, 
der(10)t(5;10)(q?31;q26), +11, +add(12)(q11), +add(12)(p11.2), +add(12)(q24), +der(12;14)(p10;q10), add(13)(p11.2), +i(13)(q10), 
add(14)(p11.2), -15, -15, der(15)add(15)(p11.2)add(15)(q26), add(16)(q22), +add(16)(q22), -17, -17, -18, add(18)(p11.2), del(19)(p13), 
add(19)(q13), -20, add(21)(p11.2), -22, i(22)(q10), +20mar, inc [cp25]
TOV-1946 51~62, X, -X, der(X;12)(q10;q10), del(1)(q41q42), +add(1)(p13), +del(1)(q12), add(2)(q37), t(3;6)(p21;p21), t(3;6)(p21;p21)x2, 
del(3)(p?14), add(4)(q35), del(5)(p12), +der(5;8)(q10;p10), der(6)t(3;6)(p10;q10)del(6)(q?21), +der(6)add(6)(p25)add(6)(q27), 
del(7)(q11.2q21), +add(7)(p11.2), add(8)(p11.2), +der(8)?t(8;12)(p12;q13), +9, +del(9)(p21), +der(9)del(9) (p13)add(9)(q32), +10, 
add(11)(p15)x2, +del(11)(p11.2), del(12)(p11.2)x2, der(13)?t(11;13)(p11.2;p11.2)x2, add(15)(p11.2)x2, + der(15)?t(8;15)(q21;p11.2), -
16, add(16)(p13), add(16)(q24), -17, add(17)(p11.2), add(17)(p1?3), add(18)(q23), +19, +add(19)(q13.4), +20, +20, -21, -
22,+22,+?22,+20mar,inc[cp22]
OV-1946 57~65, X, -X, der(X;12)(q10;q10), del(1)(q41q42), add(1)(p13), +add(1)(p13), +del(1)(q12), -2, der(2)del(2)(p?14)add(2)(q?31), 
t(3;6)(p21;p21), del(3)(p?14), +5, +del(5)(q11.2), +7, +add(7)(q11.2), +8, +add(8)(p11.2), +der(8)?t(8;12)(p12;q13), del(9)(p21), 
add(9)(q32), +add(9)(q32), +der(9)del(9)(p13)add(9)(q32), +10, +add(10)(q26), add(11)(p15)x2, +del(11)(p11.2), del(12)(p11.2), 
der(13)?t(11;13)(p11.2;p11.2)x2, add(15)(p11.2)x2, +der(15)?t(8;15)(q21;p11.2), add(16)(p13), -17, -17, add(17)(p11.2), add(17)(p1?3), 
+del(17)(p11.2), -18, +18, +19, +19, +20, +20, -21, +22, +?22, +26mar, inc [cp19]BMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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A) Representative G-banded metaphases from the TOV-2223 (cell 10) cell line Figure 4
A) Representative G-banded metaphases from the TOV-2223 (cell 10) cell line. Arrows indicate the abnormal 
chromosomes, mar: marker chromosome. B) Representative metaphases from TOV-2223 (cell 45) analyzed by SKY. The ori-
gin of several marker chromosomes (mar) is defined by SKY analysis. Other examples of G-banded metaphases and the com-
bined inverted-DAPI and SKY images of different cells are presented (see additional Files 1 and 2).BMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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A) Representative G-banded metaphases from the TOV-1946 (cell 34) cell lines Figure 5
A) Representative G-banded metaphases from the TOV-1946 (cell 34) cell lines. Arrows indicate the abnormal 
chromosomes, mar: marker chromosome. B), D), F) Representative metaphases from TOV-1946 (cell 44) cell line analyzed by 
SKY. The origin of several marker chromosomes (mar) is defined by SKY analysis. Other examples of G-banded metaphases 
and the combined inverted-DAPI and SKY images of different cells are presented (see additional Files 3 and 4).BMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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A) Representative G-banded metaphases from the OV-1946 (cell 1) cell line Figure 6
A) Representative G-banded metaphases from the OV-1946 (cell 1) cell line. Arrows indicate the abnormal chro-
mosomes, mar: marker chromosome. B) Representative metaphases from OV-1946 (cell 11) cell line analyzed by SKY. The ori-
gin of several marker chromosomes (mar) is defined by SKY analysis. Other examples of G-banded metaphases and the 
combined inverted-DAPI and SKY images of different cells are presented (see additional Files 5).BMC Cancer 2008, 8:152 http://www.biomedcentral.com/1471-2407/8/152
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lines present with unique phenotypes. Indeed, TOV-1946
cells had a better capability to invade and migrate
although their capacity to form spheroid is reduced com-
pared to the OV-1946 cells. One might speculate that cells
derived from solid tumor conserve their migration and
invasion property but in ascites, these characteristics are
less vital. It has been previously shown that cells present
in ascites form spheres or aggregates that can adhere to
different extracellular matrices as well as to normal
human mesothelial cells [68] but are not always invasive.
The role of spheroids in ascites of ovarian cancer patients
remains undefined. This is the first report of cell lines
derived both from solid tumor and ascites cells of the
same patient and further studies on these cell lines may
provide useful insights into the biological progression of
EOCs.
As both the TOV-1946 and OV-1946 injected mice devel-
oped ascites we hypothesize that the ability for cell lines
to induce ascites formation in mice is intrinsic to the given
cell line and independent of their origin (solid tumor ver-
sus ascites). It has been previously shown that the in vivo
tumorigenicity can usually be predicted by the ability of
the cells to grow in soft agar [69]. The OV-1946 cell line,
which was the most tumorigenic, also formed the largest
and most numerous colonies when seeded in soft agar
(Table 2). In previous studies we have also observed that
the capacity of the cells to form compact spheroids is
related to their ability to form tumors in vivo [70]. Consist-
ent with this notion, here we show that the OV-1946 cell
line formed the most compact spheroids among the new
cell lines and formed the greatest number of tumors with
the shortest latency in xenograft experiments. However,
the TOV-2223 cell line does not even form an aggregate in
hanging droplets, only formed small colonies in soft agar
and produced no tumors in SCID mice. The tumorigenic-
ity results for TOV-2223 are also consistent with the rela-
tive indolent disease observed in patient 2223 who
survived a relatively long period post diagnosis without
treatment. Indeed, we have previously isolated the TOV-
81D cell lines, also from an indolent disease, which failed
to form tumors in immuno-compromised mice [4] sug-
gesting inherent qualities of the tumor that are reflected in
its clinical behavior can affect this biological parameter.
The unique features of the described cell lines provide
complementary models for different aspects of the dis-
ease. For example, while TOV-2223 and the TOV-1946
cell lines are both derived from solid tumors of the same
type of serous EOC disease, they vary in important aspects
including their aggressiveness and karyotype. They may
prove useful for comparative studies to uncover molecular
events that distinguish very aggressive from more indolent
serous disease in ovarian cancer. Although the TOV-1946
and OV-1946 lines were derived from the same patient,
they were collected from the solid tumor and the corre-
sponding ascites respectively. Although common genome
modification are shared between these two cell lines (see
examples of modifications occurring on chromosome X,
1, 2, 7, 8, 9, 11, 12, 13, 15 and 16) (Table 4), others are
unique either to the solid tumor or the ascites derived cell
line (chromosome 2, 4, 5, 6, 7, 9, 16, 17, 18, 19, 20 and
22) (Table 4). These observations suggest that the two cell
lines acquired common modifications during the earlier
steps of tumorigenesis and during cancer progression dif-
ferent rearrangements were selected for, depending on the
microenvironment.
The results obtained by SKY and G-banding assays reflect
previously published karyotype studies on EOC where
high genomic instability is observed [71]. Recently, it as
been shown that recurrent rearrangements resulting in the
formation of new fusion genes could be identified using
genomic and bioinformatic tools [72-75]. So far such
studies have been difficult to conduct on solid tumors and
hence the importance of appropriate cellular models rep-
resenting different types of tumors. The future fine cartog-
raphy of recurrent lesions in these cell lines may provide
insights into the molecular events that contribute to EOC
initiation and progression.
Conclusion
In conclusion, this paper describes the establishment and
characterization of three new serous EOC cell lines
derived from two chemotherapy naïve patients. These cell
lines are new and important tools in the study ovarian
cancer disease, as few cell lines are described to date that
represent this frequently diagnosed histopathology type
of EOC. The rich characterization of these cell lines,
including epithelial marker expression, growth character-
istics, mutation and SKY analysis, provide the foundation
for future experiments using these new models of EOC.
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